Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, “window-of-opportunity” study
Sign Up to like & getrecommendations! Published in 2022 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noac263
Abstract: Abstract Background The bromodomain and extraterminal protein (BET) inhibitor trotabresib has demonstrated antitumor activity in patients with advanced solid tumors, including high-grade gliomas. CC-90010-GBM-001 (NCT04047303) is a phase I study investigating the pharmacokinetics, pharmacodynamics, and… read more here.
Keywords: high grade; grade gliomas; trotabresib; bromodomain extraterminal ... See more keywords